鲁比-鲁克索利提尼布:一种可光释放的抗瘤JAK抑制剂
Estefania Rafic1, Cindy Ma2, Bobby B Shih2
1Departamento de Química Inorgánica, Analítica y Química Física, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, INQUIMAE, CONICET, Buenos Aires C1428EHA, Argentina.
Journal of the American Chemical Society
|May 3, 2024
概括
鲁双氨酸鲁克索利丁尼布 (RuBiRuxo) 是一种新型光激活药物,在皮肤T细胞淋巴瘤模型中有效降低癌细胞生长并诱导细胞亡. 这种方法对新的光动力学疗法充满希望.
科学领域:
- 药用化学 医学化学
- 光动力学疗法 光动力学疗法
- 在瘤学瘤学.
背景情况:
- 皮肤T细胞淋巴瘤 (CTCL) 是一组影响皮肤的癌症.
- 鲁克索利提尼布是一种用于CTCL治疗的Janus激酶 (JAK) 抑制剂.
- 有针对性的药物输送和光激活疗法为改善治疗结果提供了潜力.
研究的目的:
- 为了合成和评估二二丁鲁克索利丁尼布 (RuBiRuxo) 作为一种可光释放的JAK抑制剂.
- 评估RuBiRuxo在抑制CTCL细胞增殖和在光激活时诱导亡方面的疗效.
- 为了研究作用机制,包括对STAT蛋白酸化的影响.
主要方法:
- 合成了新型的鲁 - 双氨酸 ruxolitinib (RuBiRuxo) 化合物.
- 在可见光下评估RuBiRuxo稳定性和光释放动力学.
- 在CTCL细胞系上进行体外生物测试,包括细胞增殖试验和细胞亡检测.
- 在治疗后分析STAT蛋白质酸化水平.
主要成果:
- RuBiRuxo得到了高效的合成,并在水溶液中表现出稳定性.
- 可见光迅速从RuBiRuxo化合物中光释放了鲁克索利提尼布.
- 照射RuBiRuxo显著降低了CTCL细胞的增殖和诱导光和时间依赖的方式亡.
- 观察到的抗癌效应是特异性的,并通过减少STAT蛋白的酸化来调解.
结论:
- 像RuBiRuxo这样的以为基础的光化合物代表了用于光动力学治疗的有希望的新类药物.
- 光激活的RuBiRuxo为治疗皮肤淋巴瘤提供了有针对性的方法.
- 这项研究突出了光药学在开发各种病理学的新疗法策略方面的潜力.
相关概念视频
01:20The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
01:03Rous Sarcoma Virus (RSV) and Cancer
5.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.1K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K